Curevac N.V. (CVAC)
$81.19 0.91 (1.11%)
11:23 EST CVAC Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 125,722
Day's Range 79.21 - 82.02
52-Week Range 36.15 - 85.68
Dividend & Yield N/A (N/A)
CVAC Stock Predictions, Articles, and Curevac N.V. News
- From InvestorPlace
- From the Web
Here are the latest Robinhood stocks you can buy on the popular trading app, featuring well-rounded selections from several sectors.
CureVac just announced it was launching Phase 2 trials in Peru and Panama for its coronavirus vaccine. CVAC stock is rallying in response.
CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?
By Thomas Niel
Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:GSK) Inovio (NASDAQ:INO) Johnson & Johnson (NYSE:JNJ) Moderna (NASDAQ:MRNA) Novavax (NASDAQ:NVAX)
With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.
CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?
The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed
CureVac stock has been hot since its IPO thanks to its coronavirus vaccine candidate. Here's why you should give CVAC a breather now.
CureVac has extensive collaborations globally as well as a range of drug candidates. CureVac stock is a high-risk, high-return investment.
CureVac stock soars after the company announced that it was in talks of supplying the vaccine to EU member states.
CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years.
The CureVac (CVAC) IPO is underway Friday and potential investors will want to keep an eye on the stock as it's seeing massive gains.
From The Motley Fool